Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 with Chemoradiotherapy in Esophageal/GE Junction Cancer
NCT00561197Phase 2Terminated
- Sponsor
- Ascenta Therapeutics
- Start
- Aug 2007
- Primary completion
- Sep 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of r-(-)-gossypol acetic acid in esophageal cancer and gastroesophageal junction cancer, sponsored by Ascenta Therapeutics. Primary endpoints: Safety and tolerability of AT-101 in combination with chemoradiotherapy at 1 year and Pathologic Complete Response rate at 1 year. Started Aug 2007; status: terminated.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00561197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561197.